Shipments will halt by close of business Tuesday evening, the company said. Sarepta had initially rejected the agency’s ...

The Trump FDA tries to kill a therapy that has helped boys with a deadly diagnosis.

The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...

Sarepta Therapeutics announced it has laid off more than one-third of its workforce, a drastic cost-cutting move following ...

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...

Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) plunged 13% on Friday after a major regulatory blow in Europe. The European ...

There were warnings to the FDA about Sarepta Therapeutics Inc. before US regulators asked the company to halt shipments of its gene therapy.

The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...

Sarepta Therapeutics, Inc. also has a pipeline against Limb-Girdle muscular dystrophy, which causes weakness and wasting of the muscles starting around hips and shoulders and progressing to arms ...

Cambridge-based Sarepta Therapeutics to charge $3.2M for new Duchenne muscular dystrophy treatment. First gene therapy for deadly muscle-wasting disease approved Thursday by FDA ...

Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.